{"id":877814,"date":"2025-08-21T07:09:51","date_gmt":"2025-08-21T11:09:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/"},"modified":"2025-08-21T07:09:51","modified_gmt":"2025-08-21T11:09:51","slug":"shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/","title":{"rendered":"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately."},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <b>Lead Plaintiff Deadline is <span class=\"xn-chron\">October 14, 2025<\/span><\/b>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 21, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=2450196849&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/a>\u00a0announces that a securities class action lawsuit has been filed in <span class=\"xn-location\">the United States<\/span> District Court for the Northern District of <span class=\"xn-location\">California<\/span> on behalf of all persons and entities who purchased or otherwise acquired of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (&#8220;Unicycive or the &#8220;Company&#8221;) securities between <span class=\"xn-chron\">March 29, 2024<\/span> and <span class=\"xn-chron\">June 7, 2025<\/span>, inclusive (the &#8220;Class Period&#8221;).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\" title=\"(PRNewsfoto\/Wolf Haldenstein Adler Freeman )\" alt=\"(PRNewsfoto\/Wolf Haldenstein Adler Freeman )\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p class=\"prntac\">\n        <b><br \/>\n          <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=703157270&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=PLEASE+CLICK+HERE+TO+JOIN+THE+CASE+AND+SUBMIT+CONTACT+INFORMATION\" target=\"_blank\" rel=\"nofollow\">PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/a><br \/>\n        <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Claims:<\/b>\n        <\/li>\n<\/ul>\n<p class=\"prnml40\">Investors <span>allege<\/span> violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and SEC Rule <span class=\"xn-money\">10b<\/span>-5. The suit claims Unicycive and certain officers made <b>false and misleading statements<\/b> about:<\/p>\n<ul type=\"disc\">\n<ol type=\"1\">\n<li>The company&#8217;s readiness to meet FDA manufacturing compliance requirements.<\/li>\n<li>The regulatory prospects of its lead drug candidate, <b>oxylanthanum carbonate (OLC)<\/b>, for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.\n<\/li>\n<\/ol>\n<li>\n          <b>Key Events<\/b>:<\/li>\n<\/ul>\n<ul type=\"disc\">\n<ul type=\"circle\">\n<li>\n            <b><br \/>\n              <span class=\"xn-chron\">Sept 2024<\/span><br \/>\n            <\/b>: Unicycive submitted its <b>New Drug Application (NDA)<\/b> for OLC to the FDA.<\/li>\n<li>\n            <b><br \/>\n              <span class=\"xn-chron\">June 10, 2025<\/span><br \/>\n            <\/b>: Company disclosed that the FDA found <b>deficiencies in cGMP compliance<\/b> at a third-party manufacturing subcontractor. Stock dropped <b>40.9%<\/b> to <span class=\"xn-money\">$5.32<\/span>.<\/li>\n<li>\n            <b><br \/>\n              <span class=\"xn-chron\">June 30, 2025<\/span><br \/>\n            <\/b>: FDA issued a <b>Complete Response Letter (CRL)<\/b> rejecting the OLC NDA due to the same cGMP issues. Stock fell another <b>29.9%<\/b> to <span class=\"xn-money\">$4.77<\/span>.<\/li>\n<\/ul>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <b>Lead Plaintiff Deadline<\/b>: Investors must seek lead plaintiff appointment by <b><span class=\"xn-chron\">October 14, 2025<\/span><\/b>.<\/li>\n<\/ul>\n<p>\n        <b>Why\u00a0<\/b><br \/>\n        <b><br \/>\n          <u><br \/>\n            <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=2450196849&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><br \/>\n              <span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/a><br \/>\n          <\/u><br \/>\n        <\/b><br \/>\n        <b>?<\/b><br \/>\n        <b>:<\/b>\n      <\/p>\n<p>This illustrious <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=3834454822&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=firm\" target=\"_blank\" rel=\"nofollow\">firm<\/a>, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=2242149222&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=law+firm%C2%A0\" target=\"_blank\" rel=\"nofollow\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n<p>We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=2450196849&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/a>.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Phone:<\/b>\u00a0(800) 575-0735 or (212) 545-4774<\/li>\n<li>\n          <b>Email:\u00a0<\/b><br \/>\n          <a href=\"mailto:classmember@whafh.com\" target=\"_blank\" rel=\"nofollow\">classmember@whafh.com<\/a>\n        <\/li>\n<li>\n          <b>Contact Person:<\/b>\u00a0<a href=\"mailto:gstone@whafh.com\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Gregory Stone<\/span>, Director of Case and Financial Analysis<\/a><\/li>\n<\/ul>\n<p>\n        <b>Firm Website:<\/b><br \/>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4492635-2&amp;h=4266959478&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Funicycive-therapeutics-inc%2F&amp;a=%C2%A0Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\">\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>\n      <\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY55970&amp;sd=2025-08-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-302535195.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-302535195.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY55970&amp;Transmission_Id=202508210705PR_NEWS_USPR_____NY55970&amp;DateId=20250821\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Lead Plaintiff Deadline is October 14, 2025 NEW YORK , Aug. 21, 2025 \/PRNewswire\/ &#8212;\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP\u00a0announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (&#8220;Unicycive or the &#8220;Company&#8221;) securities between March 29, 2024 and June 7, 2025, inclusive (the &#8220;Class Period&#8221;). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Claims: Investors allege violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and SEC Rule 10b-5. The suit claims Unicycive and certain officers made false and misleading &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-877814","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Lead Plaintiff Deadline is October 14, 2025 NEW YORK , Aug. 21, 2025 \/PRNewswire\/ &#8212;\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP\u00a0announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (&#8220;Unicycive or the &#8220;Company&#8221;) securities between March 29, 2024 and June 7, 2025, inclusive (the &#8220;Class Period&#8221;). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Claims: Investors allege violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and SEC Rule 10b-5. The suit claims Unicycive and certain officers made false and misleading &hellip; Continue reading &quot;Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T11:09:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.\",\"datePublished\":\"2025-08-21T11:09:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/\",\"name\":\"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"datePublished\":\"2025-08-21T11:09:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. - Market Newsdesk","og_description":"PR Newswire Lead Plaintiff Deadline is October 14, 2025 NEW YORK , Aug. 21, 2025 \/PRNewswire\/ &#8212;\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP\u00a0announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (&#8220;Unicycive or the &#8220;Company&#8221;) securities between March 29, 2024 and June 7, 2025, inclusive (the &#8220;Class Period&#8221;). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Claims: Investors allege violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and SEC Rule 10b-5. The suit claims Unicycive and certain officers made false and misleading &hellip; Continue reading \"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T11:09:51+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.","datePublished":"2025-08-21T11:09:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/","name":"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","datePublished":"2025-08-21T11:09:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-unicycive-therapeutics-inc-nasdaq-uncy-should-contact-wolf-haldenstein-immediately-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=877814"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877814\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=877814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=877814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=877814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}